[Correlation Between Metabolic Syndrome and Prognosis of Patients with Clear Cell Renal Cell Carcinoma]

Overview

Journal Beijing Da Xue Xue Bao Yi Xue Ban

Specialty General Medicine

Date 2022 Aug 11

PMID 35950385

Authors

M N Zuo

Y Q Du

L P Yu

X Dai

T Xu

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the effects of MetS on the prognosis of patients with clear cell renal cell carcinoma (ccRCC).

Methods: Clinical and pathological data and the laboratory test of ccRCC 342 patients with diverticular stones who underwent ccRCC who underwent radical or partial nephrectomy were retrospectively collected and analyzed.The patients were divided into MetS group and non-MetS group, and the subgroups were defined according to the tumor size. The overall survival (OS), cancer-specific survival (CSS), and progression-free survival (PFS) of the two groups were analyzed by univariate Cox analysis, and the subgroup analyses were also performed. Kaplan-Meier survival curve and survival analysis for OS, CSS, and PFS of the two groups and the subgroups were conducted.

Results: Univariate Cox analysis showed that MetS was a protective factor of postoperative OS [hazard ratio ()=0.551, 95%: 0.321-0.949, =0.031], CSS (=0.460, 95%: 0.234-0.905, =0.025), and PFS (HR 0.585, 95%: 0.343-0.998, =0.049) in the patients with ccRCC. In the subgroup with tumor size≤4 cm, MetS was not associated with postoperative OS (=0.857, 95%: 0.389-1.890, =0.702), CSS (=1.129, 95%: 0.364-3.502, =0.833), and PFS (=1.554, 95%: 0.625-3.864, =0.343). In the subgroup with tumor size>4 cm, Mets was a protective factor of postoperative OS (HR=0.377, 95%: 0.175-0.812, 0.013), CSS (=0.280, 95%: 0.113-0.690, =0.006), and PFS (=0.332, 95%: 0.157-0.659, =0.002); Obesity was a protective factor of postoperative CSS (=0.464, 95%: 0.219-0.981, =0.044), and PFS (=0.445, 95%: 0.238-0.833, =0.011). Kaplan-Meier survival analysis showed that the long-term survival of patients with MetS was better than those without MetS in OS (=0.029), CSS (=0.021), and PFS (0.046); for the subgroup with tumor size≤4 cm, there was no significant difference in postoperative OS (=0.702), CSS (=0.833), and PFS (=0.339) between patients with and without MetS; For the subgroup with tumor size>4 cm, the OS (=0.010), CSS (0.003), and PFS (=0.001) of patients with MetS were better than those without MetS.

Conclusion: MetS was a protective factor of postoperative OS, CSS, and PFS in the patients with ccRCC, which was more obvious in subgroup with tumor size>4 cm. And obesity, the component of MetS, was correlated with postoperative OS and CSS.

Citing Articles

Metabolic syndrome and increased susceptibility to renal cell carcinoma - a meta-analysis.

Zhou Y, Chen Y, Yang H, Xu Z, Zhuang J, Bian Q BMC Nephrol. 2025; 26(1):102.

PMID: 40012054 PMC: 11863896. DOI: 10.1186/s12882-025-04013-6.

References

Zhang Y, Wu T, Xie J, Yan L, Guo X, Xu W . Effects of metabolic syndrome on renal function after radical nephrectomy in patients with renal cell carcinoma. Int Urol Nephrol. 2021; 53(10):2127-2135. DOI: 10.1007/s11255-020-02759-6. View

Miricescu D, Balan D, Tulin A, Stiru O, Vacaroiu I, Mihai D . PI3K/AKT/mTOR signalling pathway involvement in renal cell carcinoma pathogenesis (Review). Exp Ther Med. 2021; 21(5):540. PMC: 8014975. DOI: 10.3892/etm.2021.9972. View

Luzzago S, Palumbo C, Rosiello G, Pecoraro A, Deuker M, Stolzenbach F . Metabolic Syndrome Predicts Worse Perioperative Outcomes in Patients Treated With Partial Nephrectomy for Renal Cell Carcinoma. Urology. 2020; 140:91-97. DOI: 10.1016/j.urology.2020.02.019. View

Yu Y, Gong L, Ye J . The Role of Aberrant Metabolism in Cancer: Insights Into the Interplay Between Cell Metabolic Reprogramming, Metabolic Syndrome, and Cancer. Front Oncol. 2020; 10:942. PMC: 7301691. DOI: 10.3389/fonc.2020.00942. View

Ford E . Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care. 2005; 28(11):2745-9. DOI: 10.2337/diacare.28.11.2745. View

Parker A, Lohse C, Cheville J, Thiel D, Leibovich B, Blute M . Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma. Urology. 2006; 68(4):741-6. DOI: 10.1016/j.urology.2006.05.024. View

Yao F, Bo Y, Zhao L, Li Y, Ju L, Fang H . Prevalence and Influencing Factors of Metabolic Syndrome among Adults in China from 2015 to 2017. Nutrients. 2021; 13(12). PMC: 8705649. DOI: 10.3390/nu13124475. View

Mallik R, Chowdhury T . Metformin in cancer. Diabetes Res Clin Pract. 2018; 143:409-419. DOI: 10.1016/j.diabres.2018.05.023. View

Silva A, Pereira S, Monteiro M, Araujo A, Faria G . Effect of Metabolic Syndrome and Individual Components on Colon Cancer Characteristics and Prognosis. Front Oncol. 2021; 11:631257. PMC: 7970759. DOI: 10.3389/fonc.2021.631257. View

10.

Ewertz M, Jensen M, Gunnarsdottir K, Hojris I, Jakobsen E, Nielsen D . Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol. 2010; 29(1):25-31. DOI: 10.1200/JCO.2010.29.7614. View

11.

DiNatale R, Xie W, Becerra M, Silagy A, Attalla K, Sanchez A . The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. Eur Urol Oncol. 2019; 3(1):47-56. PMC: 7236081. DOI: 10.1016/j.euo.2019.10.002. View

12.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

13.

Eskelinen T, Kotsar A, Tammela T, Murtola T . Components of metabolic syndrome and prognosis of renal cell cancer. Scand J Urol. 2017; 51(6):435-441. DOI: 10.1080/21681805.2017.1352616. View

14.

Du Y, Yang W, Liu H, Qin C, Tang X, Xu T . Perirenal Fat as a New Independent Prognostic Factor in Patients With Surgically Treated Clear Cell Renal Cell Carcinoma. Clin Genitourin Cancer. 2021; 20(1):e75-e80. DOI: 10.1016/j.clgc.2021.10.006. View

15.

Jonasch E, Walker C, Rathmell W . Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nat Rev Nephrol. 2020; 17(4):245-261. PMC: 8172121. DOI: 10.1038/s41581-020-00359-2. View

16.

Qi J, An R, Bhatti P, Spinelli J, Murphy R . Anti-hypertensive medications and risk of colorectal cancer: a systematic review and meta-analysis. Cancer Causes Control. 2022; 33(6):801-812. DOI: 10.1007/s10552-022-01570-1. View

17.

Ozbek E, Otunctemur A, Sahin S, Dursun M, Besiroglu H, Koklu I . Renal cell carcinoma is more aggressive in Turkish patients with the metabolic syndrome. Asian Pac J Cancer Prev. 2014; 14(12):7351-4. DOI: 10.7314/apjcp.2013.14.12.7351. View

18.

Liu Z, Wang H, Zhang L, Li S, Fan Y, Meng Y . Metabolic syndrome is associated with improved cancer-specific survival in patients with localized clear cell renal cell carcinoma. Transl Androl Urol. 2019; 8(5):507-518. PMC: 6842772. DOI: 10.21037/tau.2019.10.04. View

19.

Bovolini A, Garcia J, Andrade M, Duarte J . Metabolic Syndrome Pathophysiology and Predisposing Factors. Int J Sports Med. 2020; 42(3):199-214. DOI: 10.1055/a-1263-0898. View

20.

Kriegmair M, Mandel P, Porubsky S, Durr J, Huck N, Nuhn P . Metabolic Syndrome Negatively Impacts the Outcome of Localized Renal Cell Carcinoma. Horm Cancer. 2017; 8(2):127-134. PMC: 10355923. DOI: 10.1007/s12672-017-0289-2. View